Trimbow vs. Fostair + Spiriva Respimat in Severe Asthma
Trimbow (BDP/formoterol/glycopyrronium single inhaler) is likely superior to the separate regimen of Fostair plus Spiriva Respimat for severe asthma, based on recent evidence showing significant reductions in severe exacerbations and improved clinical outcomes with single-inhaler triple therapy.
Evidence Supporting Single-Inhaler Triple Therapy
The most recent and highest-quality evidence demonstrates clear advantages for Trimbow:
A 2025 network meta-analysis found that medium-dose BDP/formoterol/glycopyrronium (Trimbow) significantly reduced severe exacerbations by 35% compared to other single-inhaler triple therapies (RR 0.65,95% CrI 0.49-0.89) 1. High-dose Trimbow showed similar trends for improvement in reducing both severe and moderate-to-severe exacerbations.
The 2026 TriMaximize real-world study of 1,445 patients with moderate-to-severe asthma demonstrated that 79.5% of patients on Trimbow experienced neither exacerbations nor required systemic corticosteroids during the first year 2. Clinical remission (3-component) was achieved in 45.6% during year one and 59.3% in years two-three, with ACT scores improving by 3.9 points at 12 months (exceeding the MCID of 3 points).
Guideline Context
The 2020 NAEPP guidelines provide relevant framework, though they don't specifically address fixed triple therapy in asthma:
- For uncontrolled persistent asthma in patients ≥12 years, guidelines conditionally recommend adding LAMA to ICS-LABA (conditional recommendation, moderate certainty) 3
- The guidelines note this is a conditional recommendation, suggesting room for clinical judgment based on newer evidence
Key Advantages of Trimbow Over Separate Inhalers
1. Adherence and Device Simplification
- Single device eliminates the risk of using only one component of triple therapy
- Reduces device mismanagement errors
- The extrafine formulation ensures all three medications deposit uniformly in both large and small airways 4
2. Clinical Outcomes
- Exacerbation reduction: The network meta-analysis specifically compared single-inhaler formulations and found Trimbow superior 1
- Lung function: Real-world data shows FEV1 improvements of 142 mL at 12 months 2
- Symptom control: ACT improvements consistently exceed MCID thresholds 2
3. Dosing Considerations
Your proposed regimen (Fostair 100 mcg BDP + formoterol 60 mcg twice daily) actually delivers 200 mcg BDP daily, while:
- Medium-dose Trimbow delivers 174 mcg BDP daily (87 mcg × 2 inhalations)
- High-dose Trimbow delivers 344 mcg BDP daily (172 mcg × 2 inhalations)
The high-dose Trimbow formulation would be most comparable to your current regimen and is specifically indicated for severe asthma 4.
Practical Algorithm for Decision-Making
Choose Trimbow (high-dose 172/5/9 mcg) if:
- Patient has adherence concerns with multiple devices
- Severe asthma requiring high-dose ICS (≥200 mcg BDP equivalent daily)
- History of frequent exacerbations despite dual therapy
- Preference for simplified regimen
Consider maintaining separate inhalers (Fostair + Spiriva) if:
- Patient already well-controlled and adherent to current regimen
- Need for flexible dosing adjustments of individual components
- Cost/insurance coverage strongly favors separate inhalers
- Patient has established proficiency with both devices
Important Caveats
- Tiotropium dosing differs: Spiriva Respimat for asthma uses 2.5 mcg daily (2 inhalations of 1.25 mcg) 5, while Trimbow contains glycopyrronium 18 mcg daily—these are different LAMAs with potentially different receptor binding profiles
- Time to benefit: Maximum lung function benefits may take 4-8 weeks 5
- The evidence base for Trimbow in asthma is newer and growing, with most robust data from 2025-2026 studies 1, 2, 6
Bottom Line
For severe asthma requiring triple therapy, initiate high-dose Trimbow (172/5/9 mcg, 2 inhalations once daily) rather than maintaining separate Fostair and Spiriva inhalers, based on superior exacerbation reduction, improved adherence potential, and consistent real-world effectiveness data showing clinical remission rates approaching 60% by year two 1, 2.